Navigation Links
Sublingual immunotherapy shows promise as treatment for peanut allergy
Date:1/7/2013

CHAPEL HILL, N.C. Peanuts are one of the most common triggers of severe food-induced allergic reactions, which can be fatal, and the prevalence of peanut allergy is increasing. However, there is currently no clinical treatment available for peanut allergy other than strict dietary elimination and, in cases of accidental ingestion, injections of epinephrine.

But a new multicenter clinical trial shows promise for sublingual immunotherapy (SLIT), a treatment in which patients are given daily doses, in gradually increasing amounts, of a liquid containing peanut powder. The patients first hold the liquid under the tongue for 2 minutes and then swallow it.

The two lead authors of the study, published in the January 2013 issue of the Journal of Allergy and Clinical Immunology, are David M. Fleischer, MD, of National Jewish Health in Denver, Colo., and Wesley Burks, MD, Curnen Distinguished Professor and Chair of the Department of Pediatrics in the University of North Carolina School of Medicine.

"These results are encouraging," Burks said. "The immune response was stronger than we thought it might be, and the side effects of this treatment were relatively small. However, the magnitude of the therapeutic effect was somewhat less than we had anticipated. That's an issue we plan to address in future studies."

In the study, 40 people with peanut allergy, ages 12 to 37 years, were randomized to receive daily peanut or placebo SLIT. All were given a baseline oral food challenge of up to 2 grams of peanut powder to test how much peanut powder they could consume without symptoms.

After 44 weeks, all were given a second oral food challenge. Those who were able to consume either 5 grams, or at least 10-fold more peanut powder than their baseline amount, were considered to be responders (i.e., desensitized to peanut). At 44 weeks, 70 percent of those who received peanut SLIT were responders, compared to 15 percent of those receiving placebo. Among the peanut-SLIT responders, the median amount of peanut powder they could successfully consume increased from 3.5 to 496 milligrams. After 68 weeks, that amount increased significantly, to 996 milligrams.

Of 10,855 peanut doses given through week 44 of the study, 63.1 percent were symptom-free. When oral/pharyngeal symptoms were excluded from the analysis, 95.2 percent of doses were symptom-free.

The study concluded that peanut SLIT safely induced desensitization in a majority of participants compared to placebo, and that longer duration of therapy led to significant increases in the amount of peanut powder people could safely consume.

However, Burks cautions, this is not a treatment that people should try on their own. For now it's a treatment that should only be given by medical professionals in a carefully monitored clinical trial, he said.


'/>"/>

Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
University of North Carolina Health Care
Source:Eurekalert  

Related medicine news :

1. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
2. Antibodies reverse type 1 diabetes in new immunotherapy study
3. Immunotherapy for elderly cancer patients finds new promise in drug combination
4. Peanut therapy shows promise in treating peanut allergy
5. Research shows that a prolonged fertility window can cause recurrent miscarriage
6. PET/CT shows clear advantages over conventional staging for breast cancer patients
7. A Feinstein Institute for Medical Research Study Shows Early Cognitive Problems among Those Who Eventually Get Alzheimer's
8. Mount Sinai survey shows that nearly 1 in 3 children with food allergies experience bullying
9. HistoWiki.com's Clint Evans Announces Kindle Book Giveaway Which Shows the Missing Links from Michelle Obama's "Let's Move" Weight Loss Program
10. Study shows heart calcium scan predictive of diabetes-related death from cardiovascular disease
11. Temple researcher shows diabetes, blood pressure link to colon cancer recurrence, survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sublingual immunotherapy shows promise as treatment for peanut allergy
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global ... diseases through research, education and awareness, today announced the appointment of Timothy J. ... microbiologist, Dr. Sellati has more than 20 years of research experience with Lyme ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment Association ... professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) – ... and state and federal governments are increasingly scrutinizing the addiction treatment industry for ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... exercise more try taking a more holistic approach and use natural alternatives for ... essential oil collection is certified USDA guaranteeing that, the new line of essential ...
(Date:9/21/2017)... ... September 21, 2017 , ... A ... addiction recovery at a time when Virginia faces an opioid epidemic. ... a staggering increase of 38 percent from 2015, underscoring the need for additional ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... Sept. 5, 2017 Sapheneia and Scannerside received ... Scannerside DoseCheck is a third-party Vendor neutral CT product ... and allows compliance with current MITA standards. ... 29 DoseCheck solution is specifically designed to provide CT ... potential radiation doses over a predefined threshold. Scannerside Dose ...
Breaking Medicine Technology: